Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma by Telang, Sucheta et al.
RESEARCH ARTICLE Open Access
Phase II trial of the regulatory T cell-depleting
agent, denileukin diftitox, in patients with
unresectable stage IV melanoma
Sucheta Telang
1, Mary Ann Rasku
1, Amy L Clem
1, Karen Carter
2, Alden C Klarer
1, Wesley R Badger
1,
Rebecca A Milam
3, Shesh N Rai
4, Jianmin Pan
4, Hana Gragg
2, Brian F Clem
1, Kelly M McMasters
5, Donald M Miller
1
and Jason Chesney
1,6*
Abstract
Background: We previously found that administration of an interleukin 2/diphtheria toxin conjugate (DAB/IL2;
Denileukin Diftitox; ONTAK) to stage IV melanoma patients depleted CD4
+CD25
HIFoxp3
+ regulatory T cells and
expanded melanoma-specific CD8
+ T cells. The goal of this study was to assess the clinical efficacy of DAB/IL2 in
an expanded cohort of stage IV melanoma patients.
Methods: In a single-center, phase II trial, DAB/IL2 (12 μg/kg; 4 daily doses; 21 day cycles) was administered to 60
unresectable stage IV melanoma patients and response rates were assessed using a combination of 2-[
18 F]-fluoro-
2-deoxy-glucose (FDG)-positron emission tomography (PET) and computed tomography (CT) imaging.
Results: After DAB/IL2 administration, 16.7% of the 60 patients had partial responses, 5% stable disease and 15%
mixed responses. Importantly, 45.5% of the chemo/immuno-naïve sub-population (11/60 patients) experienced
partial responses. One year survival was markedly higher in partial responders (80 ± 11.9%) relative to patients with
progressive disease (23.7 ± 6.5%; p value < 0.001) and 40 ± 6.2% of the total DAB/IL2-treated population were alive
at 1 year.
Conclusions: These data support the development of multi-center, randomized trials of DAB/IL2 as a monotherapy
and in combination with other immunotherapeutic agents for the treatment of stage IV melanoma.
Trial registration: NCT00299689
Background
Over 40,000 people die of metastatic melanoma each
year worldwide and, in a recent review of 2,100 stage IV
melanoma patients, the median overall survival was 6.2
months, with only 25.5% alive at 1 year [1]. Melanoma
disproportionately affects young individuals and thus
displays one of the highest “loss of potential life” rates
among the adult-onset cancers (18.6 years per mela-
noma-related death) [2]. Current treatment options for
patients with metastatic melanoma include several
immunotherapeutic agents, such as high dose interleu-
kin 2 (IL-2) [3], interferon (IFN) a-2b [4-6] and
ipilimumab (an anti-cytotoxic T lymphocyte antigen-4
[CTLA4] antibody [7,8]). Unfortunately, none of these
immunological strategies have improved the median
overall survival of newly diagnosed stage IV melanoma
patients beyond 1 year.
CD4
+CD25
HIFoxp3
+ regulatory T (Treg) cells are a
subset of T cells that inhibit the activation of antigen-
specific effector T cells [9,10]. Treg cells thus are an
attractive cellular target for the development of novel
approaches to stimulate cancer immunity [11]. Deple-
tion of Treg cells in mice stimulates T cell-dependent
immune rejection of melanoma xenografts [12-14] and
Treg cells are elevated in the lymph nodes of melanoma
patients [15]. Denileukin diftitox (DAB/IL2; ONTAK) is
a recombinant fusion protein product of diphtheria
toxin and IL-2 that selectively binds to the IL-2 receptor
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any medium, provided the original work is properly cited.of cells and, following internalization, inhibits protein
synthesis, causing cell death [16]. Treg cells express
high levels of the alpha chain of the IL-2 receptor
(CD25) and a single administration of DAB/IL2 (9 or 12
μg/kg) has been found by Curiel et al.t od e p l e t eT r e g
cells in patients with metastatic ovarian, breast or squa-
mous cell lung carcinomas [17]. Furthermore, exposure
of peripheral blood mononuclear cells to DAB/IL2
reduces the T cell suppressive activity of Treg cells in
vitro [18]. Taken together, these studies suggest that
DAB/IL2 may have clinical utility for the treatment of
melanoma.
In a prior study, we examined the effect of DAB/IL2
on the peripheral blood concentration of Treg cells in
16 metastatic melanoma patients [19]. DAB/IL2 caused
a transient depletion of Treg cells that coincided with
the de novo appearance of melanoma antigen-specific
CD8
+ T cells [19]. Although the study was not designed
to assess clinical efficacy, we did observe the regression
of melanoma metastases in 3 patients. In order to better
define the clinical activity of DAB/IL2 against melanoma
and provide rationale for randomized multi-center trials,
we now have expanded this initial exploratory trial to
i n c l u d eat o t a lo f6 0s t a g eI Vm e l a n o m ap a t i e n t sa n d
will present herein the objective response rates and
results of survival analyses. We find that: (i) DAB/IL2
has significant clinical activity against stage IV mela-
noma; (ii) lack of prior exposure to chemo/immunother-
apy is associated with an increased response rate to
DAB/IL2; and (iii) patients who respond live signifi-
cantly longer than patients who experience progressive
disease. Based on the results of this study, a new rando-
mized multi-center clinical trial of DAB/IL2 has been
initiated that will correlate Treg depletion with objective
responses in chemo/immuno-naïve melanoma patients.
Methods
Trial design
This study was a single arm, open label phase II study of
DAB/IL2 undertaken from 2007 to 2010 at the James
Graham Brown Cancer Center, University of Louisville,
Louisville, Kentucky. The primary objective was to
determine the response rate of DAB/IL2 in stage IV
metastatic melanoma patients. A secondary objective
was the determination of overall survival after DAB/IL2
administration. The clinical trial registration number is
NCT00299689 (at Clinicaltrials.gov).
Patient enrollment
This clinical trial was approved by the University of
Louisville Human Subjects Committee. Only patients
with distant metastases from cutaneous, ocular, mucosal
melanoma or melanoma of unknown primary were eligi-
ble for inclusion. All patients fulfilled the following
criteria: (i) primary tumor must have been documented
by histopathologic analysis; (ii) metastatic disease must
have been documented by radiologic examinations (CT
scan or PET scan); and (iii) disease recurrences occur-
ring greater than 5 years after the original diagnosis
must have been biopsy proven. Written informed con-
sent was obtained from each patient prior to enrollment
and the trial was conducted in accordance with the
Declaration of Helsinki.
DAB/IL2 administration
All patients were subjected to fusion FDG-PET/CT or
CT imaging within 1 month prior to receiving the first
dose of DAB/IL2 and within 1 month after receiving the
last dose of DAB/IL2. DAB/IL2 (Eisai) was purchased
through third party payers and was administered as fol-
lows: 12 μg/kg, IV over 30 min every 24 h for 4 doses
(cycles repeated every 21 days; 1-4 cycles). All patients
had renal function tests, blood counts, and a complete
physical examination prior to each cycle of DAB/IL2.
The endpoint definitions were determined from qualita-
tive radiological assessments performed by board-certi-
fied radiologists after two cycles using the following
criteria:
Clinical complete response (CR): Disappearance of
all evidence of tumor. The patient must be free of
all symptoms of cancer.
Partial response (PR): 30% or greater decrease in the
sum of the longest diameter of target lesions, taking
as reference the baseline sum longest diameter.
Progressive disease (PD): At least 20% increase in
the sum of the longest diameter of target lesions,
taking as reference the baseline sum longest dia-
meter, or the appearance of new lesions and/or
unequivocal progression of existing non-target
lesions.
Stable disease (SD): Neither sufficient shrinkage to
qualify for partial response nor sufficient increase to
qualify for progressive disease, taking as reference
the smallest sum longest diameter from the start of
treatment.
M i x e dr e s p o n s e( M R ) :S i g n i f i c a n t( >3 0 % )t u m o r
regressions simultaneous with significant growth (>
20%) in individual tumors (see Figure 1B for an
example).
Adverse events were collected by reviewing the physi-
cian dictations and nursing notes during and 1 month
following the last administration of DAB/IL2.
Statistical methods
Descriptive statistics related to patient characteristics
and treatment factors were produced by outcome
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Page 2 of 10Figure 1 Examples of partial and mixed responses after DAB/IL2 administration. A. Anterior/posterior and lateral views of PET imaging
reveal a large duodenal mass (arrow) and several hepatic metastases (box) at baseline and 1 month after the final cycle of DAB/IL2. PET imaging
confirmed regression of the hepatic metastases (right panels) and a modest reduction in the duodenal mass. The increased
18 F-
fluorodeoxyglucose uptake in the left kidney is due to hydronephrosis which is unrelated to melanoma. B. After 3 cycles of DAB/IL2, this patient
experienced the marked regression of a large subcutaneous and a pelvic mass (see bottom 2 horizontal red arrows just above the bladder
[which normally contains tracer]) and a peritoneal mass (right vertical arrow). Simultaneously, enlarged paratracheal lymph nodes worsened
(upper arrows), a large conglomeration of left axillary masses expanded (dashed circle). An inferior peritoneal mass appeared and expanded (left
vertical arrow) and a superior peritoneal mass expanded and then regressed with treatment (upper horizontal arrow).
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Page 3 of 10measurements (SD+MR+PR vs. PD). The Kaplan-Meier
method was used to estimate the overall survival (OS).
Survival differences were compared using the un-
weighted log-rank test. The OS time was determined as
the time from the first day of DAB/IL2 administration
until death or last follow-up evaluation. We also fit the
univariable and multivariable logistic regression models
for the probabilities of patients with outcome SD+MR
+PR about their possible predictors. All calculations
were performed with SAS statistical software (SAS Insti-
tute Inc., Cary, NC).
Results
Baseline characteristics of study population and adverse
events
We administered four daily doses of DAB/IL2 (12 μg/kg;
2-4 21 day cycles) to a total of 60 stage IV melanoma
patients. The vast majority of patients enrolled in the
study had metastatic melanoma involving distant organs
(stage M1C; 70%) and the most commonly affected
organs were the lung (47%) and liver (47%) (Table 1).
82% of patients had been treated with at least one prior
systemic regimen and the majority were treated with
two or more prior systemic therapies. The most com-
mon previous treatment regimens included biochem-
otherapy (vinblastine, dacarbazine, cisplatin, IL-2 and
interferon alpha) and high dose IL-2 (Table 1). The
most common adverse events reported were nausea
(38%), fatigue (21%), emesis (16%), rash (15%) and chills
(10%) (Table 2) and these side effects can be easily man-
aged with symptomatic as opposed to immunosuppres-
sive agents. Interestingly, 5% of patients reported pain
associated with their tumors which may reflect inflam-
mation caused by DAB/IL2. In this trial, only one
patient developed an autoimmune disorder, vitiligo, as a
result of DAB/IL2 administration. We suspect that this
case of clinically insignificant vitiligo likely resulted from
immune cross-reactivity against antigens expressed by
both melanoma cells and melanocytes.
Examples of clinical responses to DAB/IL2
We observed several examples of partial and mixed
responses which are typical of immunotherapeutic
agents. For example, an 82 year-old male developed mul-
tiple hepatic metastases (red box, second panel; Figure
1A) and a large duodenal mass (red arrow, first panel,
Figure 1A) which caused significant nausea, vomiting and
weight loss. After four cycles of DAB/IL2, he experienced
the complete regression of his hepatic metastases con-
firmed by FDG-PET imaging and resolution of his symp-
toms but only a modest reduction in his duodenal mass
(compare Baseline to +4 Months, Figure 1A; the
increased
18 F-FDG uptake in the left kidney is due to
hydronephrosis which is unrelated to melanoma). Next,
an 83 year-old male received three cycles of DAB/IL2
and experienced marked regression of a large subcuta-
neous mass, a pelvic mass (Figure 1B, see bottom 2 hori-
zontal red arrows just above the bladder [which normally
contains tracer]) and a peritoneal mass (Figure 1B, right
vertical arrow). Simultaneously, a large conglomeration
of left axillary masses expanded (Figure 1B, dashed cir-
cle), paratracheal lymph nodes worsened (Figure 1B,
upper arrows) and a peritoneal mass appeared and
expanded with treatment (Figure 1B, left vertical arrow).
This is a typical clinical example of a mixed response to
DAB/IL2. A 78 year-old female experienced a dramatic
reduction in metastases involving the liver, lung and
bone that has persisted for 15 months with the exception
of a single small right paratracheal lymph node (Figure
2A). A 47 year-old male who had previously progressed
through high dose IL-2, biochemotherapy and several
Table 1 Baseline Characteristics
Number Percent
Sex (Male) 40 67
Ethnic Origin (Caucasian) 59 98
Age (Years) 61 (median)
Stage
M1A 10 17
M1B 8 13
M1C 42 70
Common Lesion Sites
Lung 28 47
Liver 28 47
Lymph Nodes 23 38
Subcutaneous 16 27
Bone 13 22
Spleen 3 5
Adrenal Glands 3 5
Chemo- Naïve 11 18
Prior Chemo Exposure 49 82
Previous Systemic Treatments
01 1 1 8
11 8 3 0
21 7 2 8
39 1 5
44 7
51 2
Previous Adjuvant Therapy
Dacarbazine/IL-2 16 27
IFN 5 8
Previous Active Therapy
Biochemotherapy 26 43
High Dose IL-2 8 13
Anti-CTLA4 7 12
Temozolomide 7 12
Vaccine 7 12
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Page 4 of 10experimental agents also had a marked global reduc-
tion in hepatic, lung and subcutaneous metastatic bur-
den (Figure 2B). As a final clinical example, a 62 year-
old male who progressed after receiving anti-CTLA4
and experienced debilitating right upper quadrant pain,
nausea/vomiting and fatigue associated with
widespread hepatic metastases experienced a substan-
tial partial response that was durable for at least 15
months (Figure 2C). These examples of partial but
durable clinical responses to DAB/IL2 are suggestive of
an immunotherapeutic mechanism of action for DAB/
IL2.
Objective clinical response rates based on qualitative
radiological assessments
We compared baseline FDG-PET and/or CT imaging to
follow-up scans using qualitative radiology assessments
which approximate Response Evaluation Criteria in
Solid Tumors (RECIST) criteria [20]. Importantly, any
new lesions that were identified would automatically sig-
nify progression. Figure 3A illustrates the following
response rates: partial response (PR), 16.7% (10/60);
stable disease (SD), 5% (3/60); mixed response (MR),
15% (9/60); and progressive disease (PD), 63.3% (38/60).
We observed a marked improvement in the response
rates of the 11 chemo/immuno-naïve patients: partial
response (PR), 45.5% (5/11); stable disease (SD), 9.1%
(1/11); mixed response (MR), 18.2% (2/11); and progres-
sive disease (PD), 27.3% (3/11) (Figure 3A). Univariable
and multivariable logistic modeling revealed a statisti-
cally significant increase in patients experiencing clinical
benefit (PR+SD+MR) in the chemo/immuno-naïve
population (p values = 0.011 and 0.017, respectively).
W ed i dn o to b s e r v ead e c r e a s ei nr e s p o n s er a t ef r o m
prior exposure to IL-2 (p value = 0.389, univariable
logistic model) which had been anticipated given the
potential for cross-reactivity of antibodies between
recombinant IL-2 and DAB/IL2 (data not shown). Stage
IV melanoma is sub-classified into M1A (metastases to
skin, subcutaneous tissues or distant lymph nodes; nor-
mal LDH), M1B (lung; normal LDH) and M1C (other
visceral sites or distant metastases at any site; normal
LDH; or any distant metastases; elevated LDH). We
found that the partial response rate was highest in M1A
patients (40%; Figure 3B and Table 3) and univariable
logistic modeling indicated that the combined PR+SD
+MR rate in the M1A population was higher than in
the M1B population (p v a l u e=0 . 0 2 8 )a n dt h eM 1 C
population (p value = 0.044). However, within the
chemo/immuno-naïve population, the M1C patients
experienced the greatest partial response rate (66.7%;
Figure 3D). These data suggest that patients with the
worst prognosis (i.e. M1C) seem to respond to DAB/IL2
at least as well as those with higher survival odds. No
M1B patients had a partial or mixed response and only
one did not progress (12.5%; Figure 3C). Last, although
only two mucosal and two ocular melanoma patients
were enrolled, we did observe 2/2 mixed responses and
1/2 mixed response in this small population, respectively
(data not shown).
Table 2 Adverse Events (Grade 1 + 2; ≥ 2%)
Adverse Event Number Percent
Nausea 23 38
Fatigue 13 21
Emesis 10 16
Rash 9 15
Chills 6 10
Back Pain 5 8
Weight Loss 4 7
Weakness 4 7
Pruritis 4 7
Poor Appetite 4 7
Shortness of Breath 4 7
Pain At Tumor Site 3 5
Insomnia 3 5
Lethargy 3 5
Rib Pain 2 3
Fever 3 5
Ascites 2 3
Cellulitis 2 3
Diarrhea 2 3
Pedal Edema 2 3
Hypotension 1 2
Cough 1 2
Whole Body Rash 1 2
Neck Pain 1 2
Presyncope 1 2
Malaise 1 2
Fluid Retention 1 2
Poor Oral Intake 1 2
Head Sweats 1 2
Diffuse Body Aches 1 2
Erythema 1 2
Abdominal Pain 1 2
Gait Imbalance 1 2
Pleuritis 1 2
Jaundice 1 2
Constipation 1 2
Nipple Irritation 1 2
Xerostomia 1 2
Chest Thrombosis 1 2
Vitiligo 1 2
Visual Disturbance 1 2
Diplopia 1 2
Perioral Numbness 1 2
Pruritus in Eyes 1 2
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Page 5 of 10Figure 2 Durable responses after DAB/IL2 administration. On the left, baseline anterior/posterior views of FDG-PET imaging reveal multiple
FDG-avid melanoma metastases in three clinical examples: A, 78 year-old female; B, 47 year-old male; and C, 62 year-old male. After DAB/IL2
administration, we observed a clinically significant and durable reduction in tumor burden, including hepatic metastases, pulmonary nodules,
metatastic lymph nodes and subcutaneous nodules in all three patient examples.
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Page 6 of 10Survival analyses
The median follow-up day from the first day of DAB/
IL2 was 315 days (range from 28 to 1,198 days) for all
patients and 995 days for seven patients who were alive
at the time of the last follow-up (range from 631 to
1,198 days). The 1, 2, 3 and 4 year overall survival per-
centages were 40.0%, 17.9%, 9.2% and 9.2%, respectively.
Although there appeared to be a trend towards
improved overall survival in the chemo/immuno-naïve
population (Figure 4A), the un-weighted log-rank test
did not reveal a statistically significant difference (p
value = 0.140). However, the overall survival probability
was significantly higher in the patients in stage M1A
compared to those in stage M1B (p value = 0.001), stage
M1C (p value = 0.019) and combined stage M1B+M1C
(p value = 0.010; Figure 4B) and the patients with a PR
had a statistically significant longer overall survival time
than those with the outcome PD (p value < 0.001; Fig-
ure 4C). Last, there appeared to be a trend towards
decreased overall survival at year 2 in patients who had
been previously administered recombinant IL-2 (data
not shown), however this was not statistically significant
(p value = 0.178).
Discussion
This single-center, exploratory trial demonstrated that
DAB/IL2 has significant clinical activity in stage IV mel-
anoma patients. The finding that partial responses to
DAB/IL2 were associated with longer overall survival
provides preliminary rationale for clinical trials in which
patients are randomized to DAB/IL2 or FDA-approved
agents for stage IV melanoma (i.e. IL-2, dacarbazine,
Figure 3 A. Increased partial responses to DAB/IL2 noted in chemo/immuno-naïve and stage M1A melanoma patients. Sixty stage IV
melanoma patients were administered DAB/IL2 and the objective response rates were determined using qualitative radiological assessments of
FDG-PET and CT imaging. Whereas 16.7% of all treated patients experienced partial responses, 45.5% of the chemo/immuno-naïve patients
experienced partial responses (A). Response rates were calculated based on sub-stage of melanoma. Whereas stage M1A (lymph node, skin and
subcutaneous) (B) melanoma patients experienced the highest total objective response rate, stage M1B patients had no partial responses (C) and
chemo/immuno-naïve patients with visceral metastases (stage M1C) had a > 60% partial response rate (D).
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Page 7 of 10ipilimumab or vemurafenib). Importantly, the 1 year
median overall survival of 40% in this predominantly
pre-treated stage IV melanoma population compared
favorably to the historical 1 year overall survival of
25.5% [1]. Additionally, the observed immunotherapy-
like mixed responses (e.g. Figure 1B) and partial but
durable responses (e.g. Figure 2) coupled to the known
lack of cytotoxicity of DAB/IL2 to human melanoma
cells implies that the clinical activity of DAB/IL2 may
rely in part on the known Treg-depleting effects of
DAB/IL2 [19]. However, we should note that one prior
study did not detect a depletion of Treg cells after
DAB/IL2 administration which may due to differences
in their Treg cell measurement methodologies or the
effects of prior treatments on the Treg-depleting activity
of DAB/IL2 (discussed in [21].)
Based on the high response rates in the chemo/
immuno-naïve patients (Figure 3A), a new multi-center,
sponsored phase II trial of DAB/IL2 in chemo/immuno-
naïve patients that relies on CT imaging and immune
related response criteria was initiated in Summer 2010.
This trial has been powered to correlate the clinical
effects of DAB/IL2 with the depletion of peripheral
blood Treg cells. CD8
+ T cell infiltration into tumors
and, perhaps most importantly, HLA class I expression
of the melanoma cells, will be assessed by immunohisto-
chemistry of tumors from patients who agree to
undergo biopsies. We postulate that the patients who
have the greatest Treg cell depletion may experience
more clinical responses but that certain melanoma
metastases will nevertheless grow due to immune escape
Table 3 Stages and Prior Systemic Therapies of DAB/IL2
Responders
Stage Age Prior Systemic Therapy # Cycles Response
M1A (7/10) 59 None 4 PR
78 None 2 SD
83 None 2 MR
64 ADI, BCT, aCTLA4, VAC 4 PR
60 AIFN, BCT, TEM 4 PR
45 ADI, IFN, VAC 4 PR
75 AIFN, BCT 4 SD
M1B (1/8) 67 ADI 4 SD
M1C (14/42) 78 None 2 PR
83 None 3 PR
82 None 3 PR
61 None 4 PR
59 None 4 MR
47 BCT, HDIL2, TKI258 3 PR
62 aCTLA4 4 PR
55 BCT, HDIL2, TKI258 4 MR
70 ADI, BCT 2 MR
30 BCT 4 MR
30 BCT, HDIL2, aCTLA4, TKI258 2 MR
45 BCT 4 MR
61 BCT 3 MR
58 ADI, VAC 4 MR
Abbreviations: ADI adjuvant dacarbazine/low-dose IL-2; BCT biochemotherapy;
aCTLA4 anti-cytotoxic T lymphocyte Antigen 4 antibody; VAC peptide
vaccines; TEM temozolomide; IFN interferon; AIFN adjuvant interferon; HDIL2
high-dose IL-2; TKI258 tyrosine kinase inhibitor 258
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Figure 4 High overall survival in chemo/immuno-naïve, stage
M1A and partial responders to DAB/IL2. Median overall survival
of these patients was determined using the Kaplan-Meier method
and stratified based on prior treatment exposure (A), stage (M1A-C)
(B) and response rate (C).
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Page 8 of 10through decreased HLA class I antigen expression and/
or decreased melanoma antigen expression.
The failure to mount effective immunity against mela-
noma cells likely results from a combination of attenuated
priming of naïve CD4
+ T cells due to suppression of anti-
gen presentation by dendritic cells coupled to selection for
loss of class I major histocompatibility complex (MHC)
expression in proliferating melanoma cells, negative regu-
lation by surface CTLA4 in CD4
+ and CD8
+ effector T
cells and the direct suppression of these cells by Treg
cells, among other factors [22]. We now have the clinical
tools to simultaneously activate dendritic cells both ex vivo
and in situ (e.g. with granulocyte macrophage -colony sti-
mulating factor, GM-CSF), to upregulate the expression of
class I MHC in a subset of melanoma cells with recombi-
nant interferons, to block the interaction between CTLA4
and its ligands, CD80 and CD86, with humanized antibo-
dies (e.g.i p i l i m u m a b ) ,t ot r a n s i e n t l yd e p l e t er e g u l a t o r y
cells and stimulate the peripheral blood concentration of
antigen presenting cells with DAB/IL2, and to introduce
peptide antigens that contain well-defined T cell epitopes
(e.g. gp100). While such combinations of immunothera-
peutic agents certainly have the potential to cause chronic
or potentially life-threatening autoimmunities, we believe
that the < 1 year median overall survival of stage IV mela-
noma patients supports an acceptable risk:benefit ratio for
testing in clinical trials.
Conclusions
We conclude that DAB/IL2 has significant clinical activ-
ity in unresectable stage IV melanoma patients. We
anticipate that the new phase II clinical trial of DAB/IL2
will yield definitive objective response rates that will
correlate with Treg cell depletion and that the efficacy
of this agent will be improved through the testing of
rational immunotherapeutic combinations.
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